{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:20:04Z","timestamp":1783603204695,"version":"3.55.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This was the first study to assess patient-reported outcome (PRO) trajectories among patients with relapsed\/refractory multiple myeloma (RRMM) receiving standard of care chimeric antigen receptor T-cell therapy (CAR-T) and to compare PRO trajectories by treatment group, idecabtagene vicleucel (ide-cel) vs. ciltacabtagene autoleucel (cilta-cel). Participants completed health-related quality of life (HRQOL) and symptom surveys at enrollment\/baseline (pre-lymphodepletion), infusion day(D)0, D7, D14, D21, D30, D60, and D90. Piecewise growth curve models assessed PRO trajectories pre-D7 and post-D7. Among 99 participants, ide-cel recipients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200949) were older than cilta-cel recipients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200950) (median 73 vs. 64 years,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Many PROs worsened pre-D7 and improved post-D7, including overall HRQOL, physical well-being, functional well-being, fatigue, physical function, and social function (\n                    <jats:italic>p<\/jats:italic>\n                    -values\u2009&lt;\u20090.05). Several PROs were stable pre-D7 and improved post-D7, including anxiety, sleep disturbance, pain interference, and pain intensity (\n                    <jats:italic>p<\/jats:italic>\n                    -values\u2009&lt;\u20090.05). There were differences between groups in the trajectories of social well-being pre-D7 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01) and cognitive function post-D7 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001). Patients with RRMM receiving standard of care CAR-T had similar PRO trajectories regardless of CAR-T type, with most PROs initially worsening or stable before significantly improving post-treatment. Future studies should investigate potential differences by treatment for social well-being and cognitive function as well as PRO trajectories beyond D90 post-treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41409-026-02899-w","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:45:30Z","timestamp":1778507130000},"page":"864-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-2512","authenticated-orcid":false,"given":"Laura B.","family":"Oswald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-5921","authenticated-orcid":false,"given":"Lisa M.","family":"Gudenkauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabe","family":"De Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Scheiber-Camoretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-4689","authenticated-orcid":false,"given":"Brent J.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5108-5735","authenticated-orcid":false,"given":"Brian D.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-8132","authenticated-orcid":false,"given":"Aasha I.","family":"Hoogland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvelise","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia L.","family":"Crowder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan H.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany L.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Vinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid C.","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8888","authenticated-orcid":false,"given":"Kenneth H.","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Blue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Grajales-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy","family":"Matte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kaldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Perna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-7924","authenticated-orcid":false,"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-6691","authenticated-orcid":false,"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-3711","authenticated-orcid":false,"given":"Heather S. L.","family":"Jim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Peres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2899_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00507-2","volume":"11","author":"S Jagannath","year":"2021","unstructured":"Jagannath S, Lin Y, Goldschmidt H, Reece D, Nooka A, Senin A, et al. KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood cancer J. 2021;11:1\u20139.","journal-title":"Blood cancer J"},{"key":"2899_CR2","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr. Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2899_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1182\/blood-2021-146060","volume":"138","author":"T Martin","year":"2021","unstructured":"Martin T, Usmani SZ, Berdeja JG, Jakubowiak A, Agha M, Cohen AD, et al. Updated results from CARTITUDE-1: phase 1b\/2Study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138:549.","journal-title":"Blood"},{"key":"2899_CR4","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374.","journal-title":"J Clin Oncol"},{"key":"2899_CR5","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43:2766\u201371.","journal-title":"J Clin Oncol"},{"key":"2899_CR6","unstructured":"ABECMA\u00ae(idecabtagene vicleucel)[package insert]. 2021. Celgene Corporation, a Bristol-Myers Squibb Company. https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf."},{"key":"2899_CR7","unstructured":"CARVYKTI\u00ae(ciltacabtagene autoleucel)[package insert]. 2022. Janssen Pharmaceutical Companies of Johnson & Johnson. https:\/\/www.fda.gov\/media\/156560\/download."},{"key":"2899_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"2899_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"2899_CR10","unstructured":"Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims (Food and Drug Administration). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims 2009."},{"key":"2899_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","volume":"6","author":"M Delforge","year":"2022","unstructured":"Delforge M, Shah N, Miguel JSF, Braverman J, Dhanda DS, Shi L, et al. Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Adv. 2022;6:1309\u201318.","journal-title":"Blood Adv"},{"key":"2899_CR12","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","volume":"9","author":"T Martin","year":"2022","unstructured":"Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, et al. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\u20132, open-label study. Lancet Haematol. 2022;9:e897\u2013905.","journal-title":"Lancet Haematol"},{"key":"2899_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.12882","volume":"99","author":"LK Nielsen","year":"2017","unstructured":"Nielsen LK, Jarden M, Andersen CL, Frederiksen H, Abildgaard N. A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur J Haematol. 2017;99:3\u201317.","journal-title":"Eur J Haematol"},{"key":"2899_CR14","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/S2352-3026(24)00005-X","volume":"11","author":"M Delforge","year":"2024","unstructured":"Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, et al. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024;11:e216\u201327.","journal-title":"Lancet Haematol"},{"key":"2899_CR15","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","volume":"12","author":"R Mina","year":"2025","unstructured":"Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Minnema MC, et al. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. Lancet Haematol. 2025;12:e45\u201356.","journal-title":"Lancet Haematol"},{"key":"2899_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/bjc.2013.725","volume":"110","author":"CM Booth","year":"2014","unstructured":"Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110:551\u20135.","journal-title":"Br J Cancer"},{"key":"2899_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41571-019-0167-7","volume":"16","author":"CM Booth","year":"2019","unstructured":"Booth CM, Karim S, Mackillop WJ. Real-world data: towards achieving the achievable in cancer care. Nat Rev Clin Oncol. 2019;16:312\u201325.","journal-title":"Nat Rev Clin Oncol"},{"key":"2899_CR18","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/JOP.2015.004929","volume":"11","author":"AP Mitchell","year":"2015","unstructured":"Mitchell AP, Harrison MR, Walker MS, George DJ, Abernethy AP, Hirsch BR. Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice. J Oncol Pr. 2015;11:491\u20137.","journal-title":"J Oncol Pr"},{"key":"2899_CR19","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.3390\/cancers15194711","volume":"15","author":"LB Oswald","year":"2023","unstructured":"Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, et al. Patient-reported outcomes among multiple myeloma patients treated with standard of care idecabtagene vicleucel. Cancers. 2023;15:4711.","journal-title":"Cancers"},{"key":"2899_CR20","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1200\/JCO-24-01730","volume":"43","author":"DK Hansen","year":"2025","unstructured":"Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, et al. Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43:1597\u2013609.","journal-title":"J Clin Oncol"},{"key":"2899_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70070","volume":"9","author":"M Merz","year":"2025","unstructured":"Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, et al. Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: an international multicenter study. HemaSphere. 2025;9:e70070.","journal-title":"HemaSphere"},{"key":"2899_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42:377\u201381.","journal-title":"J Biomed Inf"},{"key":"2899_CR23","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","volume":"25","author":"R Chakraborty","year":"2019","unstructured":"Chakraborty R, Sidana S, Shah GL, Scordo M, Hamilton BK, Majhail NS. Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities. Biol Blood Marrow Transpl. 2019;25:e155\u201362.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2899_CR24","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.3390\/cancers14112742","volume":"14","author":"LB Oswald","year":"2022","unstructured":"Oswald LB, Li X, Carvajal R, Hoogland AI, Gudenkauf LM, Hansen DK, et al. Longitudinal collection of patient-reported outcomes and activity data during CAR-T therapy: feasibility, acceptability, and data visualization. Cancers. 2022;14:2742.","journal-title":"Cancers"},{"key":"2899_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00005650-199601000-00006","volume":"34","author":"JN Katz","year":"1996","unstructured":"Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review?. Med Care. 1996;34:73\u201384.","journal-title":"Med Care"},{"key":"2899_CR26","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351.","journal-title":"J Clin Epidemiol"},{"key":"2899_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Tr. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Tr"},{"key":"2899_CR28","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","volume":"11","author":"DF Cella","year":"1993","unstructured":"Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570\u20139.","journal-title":"J Clin Oncol"},{"key":"2899_CR29","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1002\/cncr.28758","volume":"120","author":"T Pearman","year":"2014","unstructured":"Pearman T, Yanez B, Peipert J, Wortman K, Beaumont J, Cella D. Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. Cancer. 2014;120:2902\u20139.","journal-title":"Cancer"},{"key":"2899_CR30","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/01.mlr.0000258615.42478.55","volume":"45","author":"D Cella","year":"2007","unstructured":"Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care. 2007;45:S3\u201311.","journal-title":"Med Care"},{"key":"2899_CR31","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s11136-018-1842-3","volume":"27","author":"RD Hays","year":"2018","unstructured":"Hays RD, Spritzer KL, Schalet BD, Cella D. PROMISA (R)-29 v2.0 profile physical and mental health summary scores. Qual Life Res. 2018;27:1885\u201391.","journal-title":"Qual Life Res"},{"key":"2899_CR32","unstructured":"HealthMeasures. PROMIS(R) Score Cut Points. Northwestern University. 2023. https:\/\/www.healthmeasures.net\/score-and-interpret\/interpret-scores\/promis\/promis-score-cut-points."},{"key":"2899_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.burns.2022.11.012","volume":"49","author":"GJ Carrougher","year":"2023","unstructured":"Carrougher GJ, Bamer AM, Mason S, Stewart BT, Gibran NS. Defining numerical cut points for mild, moderate, and severe pain in adult burn survivors: a northwest regional burn model system investigation. Burns. 2023;49:310\u20136.","journal-title":"Burns"},{"key":"2899_CR34","unstructured":"R: A language and environment for statistical computing. R Foundation for Statistical Computing; 2022. https:\/\/www.R-project.org\/."},{"key":"2899_CR35","unstructured":"Mulder J. Hamaker E. The RI-CLPM & Extensions. 2022. https:\/\/jeroendmulder.github.io\/RI-CLPM\/index.html."},{"key":"2899_CR36","doi-asserted-by":"crossref","unstructured":"Rosseel Y. An R package for structural equation modeling. J Stat Softw. 2012;48:1\u201336.","DOI":"10.18637\/jss.v048.i02"},{"key":"2899_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.clml.2022.10.001","volume":"23","author":"AD Cohen","year":"2023","unstructured":"Cohen AD, Hari P, Htut M, Berdeja JG, Usmani SZ, Madduri D, et al. Patient perceptions regarding ciltacabtagene autoleucel treatment: qualitative evidence from interviews with patients with relapsed\/refractory multiple myeloma in the CARTITUDE-1 study. Clin Lymphoma Myeloma Leuk. 2023;23:68\u201377.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2899_CR38","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium. J Clin Oncol. 2023;41:2087\u201397.","journal-title":"J Clin Oncol"},{"key":"2899_CR39","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Patel KK, Peres LC, Kocoglu MH, Shune L, Simmons G, et al. Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8012.","journal-title":"J Clin Oncol"},{"key":"2899_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-77210-2","volume":"14","author":"HJ Park","year":"2024","unstructured":"Park HJ, Jeong H, Yim HW, Kim NJ. Patient-reported outcomes of chimeric antigen receptor T-cell therapy in hematologic malignancies: a systematic review and meta-analysis. Sci Rep. 2024;14:25752.","journal-title":"Sci Rep"},{"key":"2899_CR41","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jtct.2022.05.015","volume":"28","author":"A Barata","year":"2022","unstructured":"Barata A, Hoogland AI, Kommalapati A, Logue J, Welniak T, Hyland KA, et al. Change in patients\u2019 perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma. Transplant Cell Ther. 2022;28:401\u2013e1.","journal-title":"Transplant Cell Ther"},{"key":"2899_CR42","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jtct.2024.12.020","volume":"31","author":"AI Hoogland","year":"2025","unstructured":"Hoogland AI, Li X, Modi K, Welniak T, Rodriguez Y, Irizarry-Arroyo N, et al. Real-world patient-reported and neurocognitive outcomes in the year after axicabtagene ciloleucel. Transplant Cell Ther. 2025;31:157.e1-157.e13.","journal-title":"Transplant Cell Ther"},{"key":"2899_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693016","volume":"12","author":"JW Fischer","year":"2021","unstructured":"Fischer JW, Bhattarai N. CAR-T cell therapy: mechanism, management, and mitigation of inflammatory toxicities. Front Immunol. 2021;12:693016.","journal-title":"Front Immunol"},{"key":"2899_CR44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","volume":"28","author":"N Ahmed","year":"2022","unstructured":"Ahmed N, Shahzad M, Shippey E, Bansal R, Mushtaq MU, Mahmoudjafari Z, et al. Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplant Cell Ther. 2022;28:358\u201364.","journal-title":"Transplant Cell Ther"},{"key":"2899_CR45","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1002\/cam4.4797","volume":"11","author":"J Emole","year":"2022","unstructured":"Emole J, Lawal O, Lupak O, Dias A, Shune L, Yusuf K. Demographic differences among patients treated with chimeric antigen receptor T-cell therapy in the United States. Cancer Med. 2022;11:4440\u20138.","journal-title":"Cancer Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02899-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02899-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02899-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:59:12Z","timestamp":1783601952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02899-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2899"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02899-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted with support from the Participant Research, Interventions, and Measurement (PRISM) Core and funded in part by a Pentecost Family Myeloma Research Center award (MPIs: DKH, LBO, LCP) at Moffitt Cancer Center, an NCI-designated Comprehensive Cancer Center (P30CA076292). The authors have the following competing interests to disclose: LBO: Research funding: the National Institutes of Health and the Department of Defense. BDG: Consulting: Janssen; Advisory board\/honoraria: Elly Health; Patents, royalties, or other intellectual property: licensing fees received by Moffitt Cancer Center. RCB: Advisory board: Janssen, Bristol-Myers Squibb, Pfizer, and GSK; Research funding: Bristol-Myers Squibb, Janssen, Abbvie, Karyopharm, and Regeneron. KHS: Honoraria: Abbvie, Adaptive, Amgen, Bristol Myers Squibb, Janssen, Karyopharm, Kite\/Arcellx, Regeneron, Sanofi, and Takeda; Research funding to the institution outside the submitted work: AbbVie, Pfizer, and Karyopharm. BB: Consulting: Pfizer Pharmaceutics, Janssen Pharmaceutics, Oncopeptides, Kite Pharmaceuticals, and Sanofi Pharmaceutics; Honoraria: Abbvie. AGC: Advisory board: Cellectar, Janssen, and Sanofi; Speaker bureau: Amgen and Sanovi. FP: Research funding: the National Institutes of Health. MA: Advisory board: Janssen, Bristol-Myers Squibb, and Sanofi; Research funding: Janssen, Bristol-Myers Squibb, Pfizer, and Sanofi. CLF: Honoraria\/consulting: Bristol-Myers Squibb, Seattle Genetics, Cellgene, AbbVie, Sanofi, Incyte, Amgen, ONK therapeutics, and Janssen; Research funding: Bristol-Myers Squibb, Janssen, and Roche\/Genentech. OCP: Honoraria\/Consulting: Legend Biotech Inc, Bristol Myers Squibb, and Janssen Biotech Inc. TN: Clinical trial support: Novartis and Karyopharm. FLL: Advisory\/consulting: A2, Allogene, Amgen, Bluebird Bio, Bristol-Myers Squibb\/Celgene, Calibr, Caribou, Cellular Biomedicine Group, Cowen, Daiichi Sankyo, EcoR1, Emerging Therapy Solutions, GammaDelta Therapeutics, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Takeda, Wugen, Umoja, and Phizer; Contracts for service: Kite Pharma (Institutional), Allogene (Institutional), CERo Therapeutics (Institutional), Novartis (Institutional), BlueBird Bio (Institutional), Bristol-Myers Squibb (Institutional), National Cancer Institute, and the Leukemia and Lymphoma Society; Patents, royalties, other intellectual property: several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy; Education or editorial activity: Aptitude Health, ASH, BioPharma Communications CARE Education, Clinical Care Options Oncology, Imedex, and the Society for Immunotherapy of Cancer. HSLJ: Consulting: SBR Biosciences; Research funding: Kite Pharma. LCP: Research funding: Bristol-Myers Squibb, Karyopharm, Janssen, the National Institutes of Health, and the Department of Defense; Support for attending Tandem ASTCT\/CIMBTR Annual Meeting (2023). DKH: Consulting or advisory role: Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma\/Gilead Sciences, AstraZeneca, and Karyopharm; Research funding: Bristol-Myers Squibb, Janssen, Karyopharm, Kite Pharma, and Adaptive Biotech. The other authors have no competing interests to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}